Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979268 | 0.96 | FFAR1 (0.43) | FFAR1PTGER4CD274 | |
| SCHEMBL3983858 | 0.96 | FFAR1 (0.42) | FABP3FABP4FABP5FFAR1PTGER4 | |
| SCHEMBL28752668 | 0.90 | PTGER4 (0.44) | FABP3FABP4FABP5FFAR1PTGER4 | |
| SCHEMBL3973638 | 0.86 | FABP3 (0.43) | FABP3FABP4FABP5FFAR1PTGER4 | |
| SCHEMBL27605311 | 0.85 | PTGER4 (0.44) | FABP3FABP4FABP5FFAR1PTGER4 | |
| SCHEMBL3977706 | 0.85 | TDP1 (0.41) | FFAR1PTGER4LMNANPSR1MAOB | |
| SCHEMBL3979344 | 0.84 | SMPD1 (0.47) | MAOBNPC1MAPTRAB9A | |
| SCHEMBL3982728 | 0.82 | MAPT (0.41) | FABP3FABP4FABP5FFAR1PTGER4 | |
| SCHEMBL3977064 | 0.82 | ADCYAP1R1 (0.39) | — | |
| SCHEMBL3980972 | 0.82 | FFAR1 (0.40) | FABP3FABP4FABP5FFAR1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514452-B2 | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1489077-A1 | 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | GLP1R, GCGR, GPR119 | FABP3 1207/4885FABP4 1815/4885FABP5 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.